Monoclonal antibody against ovarian cancer cells (OVB-3)

Details Monoclonal antibody against ovarian cancer cells (OVB-3) Monoclonal antibody against ovarian cancer cells (OVB-3)

1986-07-24

1989-02-21

Warden, Robert J.

Drug, bio-affecting and body treating compositions

Lymphokine

436518, 436519, 436548, 514 2, 530387, G01N 3353, G01N 33543, A61K 3900, A61K 4502

Patent

active

048064947

ABSTRACT:
Monoclonal antibodies are produced which specifically bind to human ovarian cancer cells. These antibodies are conjugated to Pseudomonas exotoxin in order to produce an immunotoxin suitable for the chemotherapeutic treatment of human ovarian cancer.

REFERENCES:
patent: 4545985 (1985-10-01), Paston et al.
patent: 4664911 (1987-05-01), Uhr et al.
patent: 4666845 (1987-05-01), Mattes et al.
patent: 4671958 (1987-06-01), Rodwell et al.
patent: 4678667 (1987-07-01), Meaves et al.
Thorpe et al., "Monoclonal Antibody-Toxin Conjugates: Aiming the Magic Bullet", Monoclonal Antibodies in Clinical Medicine, McMichael et al., ed., Academic Press, London (1982), pp. 168-201.

Affiliated with

Also associated with

Rating

Monoclonal antibody against ovarian cancer cells (OVB-3) does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Monoclonal antibody against ovarian cancer cells (OVB-3), we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Monoclonal antibody against ovarian cancer cells (OVB-3) will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1521961